@article{98179fbced2945cb9682f5410d9f5fbb,
title = "Does Variant Histology Change Management of Non-muscle-invasive Bladder Cancer?",
abstract = "A 52-yr-old man, 35 pack-year smoker, is diagnosed with two non-muscle-invasive urothelial tumors, pTa and pT1, the former upstaged to pT1 by a reference pathologist. Two possible treatment strategies include intravesical bacillus Calmette-Gu{\'e}rin (BCG) and/or primary or rescue cystectomy. The importance or even accurate existence of “variant histology” is put into perspective, and whether the reference pathologist's diagnosis of a micropapillary variant requires a real change in treatment strategy is considered. Patient summary: The reference urologist diagnosed two small bladder tumors as two different depths of infiltration: one as pTa and the other (slightly more severe) as pT1. Suspecting a variant, the reference urologist referred to a second pathologist, who upstaged the less severe tumor to T1, with both defined as micropapillary cancer. This presentation discusses removal of the bladder versus a trial of treatment with bladder preservation.",
keywords = "Bacillus Calmette-Gu{\'e}rin, ERBB2, HER2, Micropapillary differentiation, Radical cystectomy, Variant histology",
author = "Maximilian Burger and Kamat, {Ashish M.} and David McConkey",
note = "Funding Information: Financial disclosures: Maximilian Burger certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Maximilian Burger acknowledges the following support: consultancies: Cepheid, Medac Pharma, MSD, and BMS; honoraria: Medac Pharma, MSD, and BMS. Ashish M. Kamat acknowledges the following support: grants or funding: BMS, CEC Oncology, FKD, Merck, and Photocure; consultancies: Abbott Molecular, Arquer, Asieris, AstraZeneca, BioClin Therapeutics, BMS, Cepheid, Cold Genesys, Eisai, Ferring, IBCG, MDxHealth, Medac, Merck, Pfizer, Photocure, Roviant, Theralase, and US Biotest; royalties or patents: CyPRIT (Cytokine Predictors of Response to Intravesical Therapy)-joint with UT Anderson Cancer Center. David McConkey acknowledges the following support: grants or funding: AstraZeneca; honoraria: Janssen and BioClin. Publisher Copyright: {\textcopyright} 2019 The Authors",
year = "2021",
month = jun,
doi = "10.1016/j.euo.2019.06.012",
language = "English (US)",
volume = "4",
pages = "510--514",
journal = "European Urology Oncology",
issn = "2588-9311",
publisher = "Elsevier BV",
number = "3",
}